Merging bioresponsive release of insulin-like growth factor I with 3D printable thermogelling hydrogels
Beudert M, Hahn L, Horn A, Hauptstein N, Sticht H, Meinel L, Luxenhofer R, Gutmann M, Luehmann T (2022)
Publication Type: Journal article, Original article
Publication year: 2022
Journal
Book Volume: 347
Pages Range: 115-126
DOI: 10.1016/j.jconrel.2022.04.028
Abstract
3D printing of biomaterials enables spatial control of drug incorporation during automated manufacturing. This study links bioresponsive release of the anabolic biologic, insulin-like growth factor-I (IGF-I) in response to matrix metalloproteinases (MMP) to 3D printing using the block copolymer of poly(2-methyl-2-oxazoline) and thermoresponsive poly(2-n-propyl-2-oxazine) (POx-b-POzi). For that, a chemo-enzymatic synthesis was deployed, ligating IGF-I enzymatically to a protease sensitive linker (PSL), which was conjugated to a POx-b-POzi copolymer. The product was blended with the plain thermogelling POx-b-POzi hydrogel. MMP exposure of the resulting hydrogel triggered bioactive IGF-I release. The bioresponsive IGF-I containing POx-b-POzi hydrogel system was further detailed for shape control and localized incorporation of IGF-I via extrusion 3D printing for future applications in biomedicine and biofabrication.
Authors with CRIS profile
Anselm Horn
Erlangen National High Performance Computing Center (NHR@FAU)
Heinrich Sticht
Professur für Bioinformatik
Additional Organisation(s)
Involved external institutions
Germany (DE)How to cite
APA:
Beudert, M., Hahn, L., Horn, A., Hauptstein, N., Sticht, H., Meinel, L.,... Luehmann, T. (2022). Merging bioresponsive release of insulin-like growth factor I with 3D printable thermogelling hydrogels. Journal of Controlled Release, 347, 115-126. https://dx.doi.org/10.1016/j.jconrel.2022.04.028
MLA:
Beudert, Matthias, et al. "Merging bioresponsive release of insulin-like growth factor I with 3D printable thermogelling hydrogels." Journal of Controlled Release 347 (2022): 115-126.
BibTeX: Download